Sign In

Communications of the ACM

ACM News

How Generative AI Could Lower Healthcare Costs, Speed Up Drug Development

View as: Print Mobile App Share:
The GPT-3 logo.

Absci executives are confident generative AI programs will lead to antibodies with high efficacy in binding to disease targets.

Credit: OpenAI

When OpenAI's GPT-3 natural language processing software burst on the scene in 2020, one of the most remarkable things about it was its ability to carry out a variety of tasks in a "zero-shot" fashion. Zero-shot fashion means without having been given any explicit examples of the task, such as printing the French word "rate" when a person types the phrase "translate the word spleen into French," despite never being trained explicitly to translate.

In the near future, AI programs may be able to develop new cancer drugs in a zero-shot fashion, inventing combinations of amino acids that bind to cancer cells and neutralize them with no prior example of an effective protein.

From ZDNet
View Full Article



No entries found

Sign In for Full Access
» Forgot Password? » Create an ACM Web Account